Prosecution Insights
Last updated: August 06, 2026

Evia Law PLC

5 pending office actions • 2 clients • 5 examiners • 4 art units • 0 of 5 (0%) have an AI response strategy ready

Quality Metrics (n=35 apps, methodology: how we score firms)

84.6%
Allowance Rate
n=35
+0.64σ
Allowance Rate (norm)
n=35
OAs to Allowance
n=11 (min 20)
OAs to Allow (norm)
n=11 (min 20)
Time to Allowance
n=11 (min 20)
+22.2pp
Interview Lift
n=35
69.2%
RCE Rate
n=35
3.3%
Appeal Rate
n=35

Rejection Performance (% of received rejections ultimately overcome)

§101 Overcome
n=1 (min 20)
§102 Overcome
n=11 (min 20)
§103 Overcome
n=17 (min 20)
§112 Overcome
n=11 (min 20)

Specialization & Scale

A61K, B82Y, G01N
Top CPC Subclasses
31%
Top-3 CPC Share
n=35
2
Practitioners
n=35
17.5
Apps / Practitioner
n=35

Portfolio Summary

5
Total Pending OAs
1
Non-Final OAs
4
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (20%)
2
Medium (40%)
2
Easy (40%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (20%)
§112 only1 (20%)
Double-patenting only1 (20%)
Double-patenting + other1 (20%)
Multi-statute (no §101)1 (20%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
ESPINOSA, CLAUDIA EDILMA 1 52.9% +56.1%
GATES, BRADFORD M 1 74.6% +24.0%
NIEBAUER, RONALD T 1 41.0% +33.6%
DABKOWSKI, ERINNE R 1 55.9% +69.2%
FRITCHMAN, REBECCA M 1 45.7% +35.8%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18041289 PEPTIDES AND FORMULATIONS FOR CANCER TREATMENT NIEBAUER, RONALD T 44d overdue

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
19204171 CHEMOTHERAPEUTIC PACLITAXEL BASED MICELLULAR NANOPARTICLES ESPINOSA, CLAUDIA EDILMA 73d overdue
18041289 PEPTIDES AND FORMULATIONS FOR CANCER TREATMENT NIEBAUER, RONALD T 44d overdue
18847313 METHOD OF MAKING BORON NITRIDE NANOTUBES AND REACTION CHAMBER THEREFORE GATES, BRADFORD M 71d
17634975 PALM FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY INCIDENTAL TO THE TREATMENT OF CANCER DABKOWSKI, ERINNE R
17615441 HIGH-BRIGHTNESS FLUOROPHORES BY COVALENT FUNCTIONALIZATION FRITCHMAN, REBECCA M

Client Portfolio (2 clients)

Top Art Units

Art UnitApps
16542
17131
16581
17581

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
19204171 CHEMOTHERAPEUTIC PACLITAXEL BASED MICELLULAR NANOPARTICLES Peptinovo Biopharma, Inc. ESPINOSA, CLAUDIA EDILMA 1654 §102§103§112DP Final Rejection 73d overdue Pending May 09, 2025
18847313 METHOD OF MAKING BORON NITRIDE NANOTUBES AND REACTION CHAMBER THEREFORE Michigan Technological University GATES, BRADFORD M 1713 §112 Final Rejection 71d Pending Sep 16, 2024
18041289 PEPTIDES AND FORMULATIONS FOR CANCER TREATMENT Peptinovo Biopharma, Inc. NIEBAUER, RONALD T 1658 §102§103§112Other Non-Final OA 44d overdue Pending Feb 10, 2023
17634975 PALM FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY INCIDENTAL TO THE TREATMENT OF CANCER Peptinovo Biopharma, Inc. DABKOWSKI, ERINNE R 1654 DP Final Rejection Pending Feb 12, 2022
17615441 HIGH-BRIGHTNESS FLUOROPHORES BY COVALENT FUNCTIONALIZATION Michigan Technological University FRITCHMAN, REBECCA M 1758 §103Other Final Rejection Pending Nov 30, 2021

Managing Evia Law PLC's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month